NCT00362271已完成1 期
Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects
Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2006年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Multiple dose PK parameters for venlafaxine+metabolite when administered alone and with aripiprazole will be derived. Cmin for aripiprazole,dehydro-aripiprazole will be measured
研究概览
简要总结
The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of venlafaxine in healthy subjects. The safety and tolerability of aripiprazole and venlafaxine co-administration will also be studied.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female subjects, ages 18 to 45 (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized.
- •Body Mass Index (BMI) of 18 to 33 kg/m2, inclusive.
排除标准
- •Subjects with a decrease in SBP of >=20 mm Hg and increase in HR of >=20 bpm after 2 minutes standing vs. 2 minutes supine at screening or with frank orthostatic hypotension at screening.
- •Supine BP of 90/50 mm Hg or lower at screening
- •SBP >=140 mm Hg or DBP >=90 mm Hg at screening
研究组 & 干预措施
1
Other
干预措施: Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg. (Drug)
结局指标
主要结局
Multiple dose PK parameters for venlafaxine+metabolite when administered alone and with aripiprazole will be derived. Cmin for aripiprazole,dehydro-aripiprazole will be measured
次要结局
- Safety will be based on review of AEs, VS, ECGs, physical exam, clinical labs
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Aripiprazole and Lexapro Drug Interaction StudyHealthyNCT00361790Otsuka Pharmaceutical Development & Commercialization, Inc.25
已完成
1 期
Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I DisorderBipolar DisorderNCT00321516Otsuka Pharmaceutical Development & Commercialization, Inc.20
已完成
4 期
Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar DisordersBipolar DisordersMetabolic ComplicationNCT00845988Seoul National University Hospital28
Unknown
2 期
A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine DependenceCocaine DependenceSchizophreniaNCT00737256Paul Saenger44
尚未招募
不适用
To study therapeutic efficacy of aripiprazole augmentation in treatment resistant obsessive compulsive disorderCTRI/2021/04/032524GMC medical college